AbbVie Completes Pharmacyclics Acquisition

AbbVie has completed the acquisition of Pharmacyclics, a deal the Chicago-based US drugmaker says enhances its scientific and commercial presence in oncology. As a wholly owned Abbevie subsidiary, Pharmacyclics will continue to be based at Sunnyvale California.

The California firm is recognized as a leader in the hematological oncology market with its Imbruvica (ibrutinib) BTK-inhibitor used to treat hematological cancers.

Approved for use in four indications in the US, Imbruvic is claimed to be the only product to have received three Breakthrough Therapy designations by the Food and Drug Administration (FDA). In partnership with Johnson & Johnson's Janssen subsidiary Janssen Biotech the drug is now approved in nearly 50 countries.

"The companies' shared expertise, combined with AbbVie's broad late-stage oncology pipeline, has the potential to transform the cancer treatment landscape for hematological malignancies and improve patient outcomes and quality of life," said Richard A. Gonzalez, CEO of AbbVie, which will market the drug in the US.

In its oncology pipeline, AbbVie has five late-stage assets in clinical development planned to be launched within the next several years. Two programs, venetoclax, a Bcl-2 inhibitor, and duvelisib, a dual PI3 kinase inhibitor, are in development for hematological cancers.

The Chicago drugmaker said it intends to explore its pipeline assets in combination with Imbruvica to evaluate the potential for meaningful improvement beyond the current standard of care.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.